Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation reports developments in synthetic biology built around its silicon-based DNA synthesis platform. Company updates cover synthetic DNA tools and services for diagnostics, therapeutics, industrial, agriculture and research markets, including oligos, genes, proteins, libraries, characterization data, antibody discovery solutions and NGS workflow tools.
Recurring announcements include fiscal results, business updates, product launches such as expanded clonal gene capabilities and library preparation kits, antibody discovery licensing, investor presentations and Nasdaq inducement equity awards for new employees.
Twist Bioscience (NASDAQ: TWST) announced that CEO Emily M. Leproust and CFO Adam Laponis will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026 at 10:00 a.m. CT in Chicago.
The presentation will be webcast live via the investor relations Investor Calendar page, with a replay available for 30 days.
Twist Bioscience (NASDAQ: TWST) announced inducement equity awards totaling 115,279 awards to 53 newly hired individuals: 101,931 restricted stock units (RSUs) and up to 13,348 performance stock units (PSUs).
RSUs largely vest over 48 months with standard 25% one-year cliff or quarterly vesting; PSUs vest based on performance metrics by fiscal 2027 (0%-150% payout range).
Twist Bioscience (NASDAQ: TWST) expanded its clonal genes portfolio with the early access launch of Complex Genes, enabling synthesis of sequences up to 7,000 base pairs and claiming acceptance of ~99.5% of clonal gene orders and ~99.9% of all DNA products. The offering targets AI-enabled drug discovery and nucleic acid therapeutics by producing difficult elements (repeats, inverted/long repeats, extreme GC) at commercial scale using its silicon-based synthesis platform and enhanced downstream processes.
Twist Bioscience (NASDAQ: TWST) announced its fiscal 2026 second quarter results for the period ended March 31, 2026 and scheduled a conference call and live webcast at 8:00 a.m. ET on May 4, 2026 to discuss results and business updates.
Investors can register on the company's Investor Relations site to receive dial‑in and PIN details; the webcast replay will be available for two weeks. The detailed earnings report and investor presentation are posted on the Investor Relations Events and Presentations page.
Twist Bioscience (NASDAQ: TWST) will report fiscal 2026 second quarter results for the period ended March 31, 2026, before market open on May 4, 2026.
The company will host a live conference call and webcast at 8:00 AM ET, and an Investor Day for analysts and institutional investors on May 21, 2026 with facility tours and management presentations.
Twist Bioscience (NASDAQ: TWST) said CEO Emily M. Leproust and CFO Adam Laponis will take part in investor fireside chats at three upcoming conferences: TD Cowen on March 3, 2026 (1:50 PM ET), Barclays on March 10, 2026 (3:00 PM ET), and Leerink on March 11, 2026 (8:40 AM ET).
According to the company, each session will be webcast live via the Investor Calendar on the investor relations website, with replays archived for 30 days after each event.
Twist Bioscience (NASDAQ: TWST) entered a licensing agreement to become co-exclusive provider of Invenra's B-Body® bispecific antibody platform, expanding Twist's antibody discovery services to include bispecifics and AI-enabled workflows.
Financial terms include an upfront payment of $5M cash plus $15M in Twist common stock, a $13.8M preferred-stock transaction to acquire ~6% of Invenra, and a 20% royalty payable to Invenra on license revenue. Twist will receive bispecific discovery and license revenues.
Twist Bioscience (NASDAQ: TWST) launched two library preparation kits: the Twist TrueAmp Library Preparation Kit and the Twist PCR-Free WGS Library Preparation Kit on February 10, 2026. Both kits use in-house engineered enzymes (a new polymerase and ligase) to improve coverage, reduce bias, and support low-input or degraded samples for NGS and WGS workflows.
Key technical highlights include compatibility with Twist HT-UDI adapters for up to 3,072 unique indexes, UMI adapters, and support for full-length UDI barcoding for up to 1,536 samples.
Twist Bioscience (NASDAQ: TWST) announced inducement equity awards totaling 114,869 awards—107,742 restricted stock units (RSUs) and up to 7,127 performance stock units (PSUs)—to 52 newly hired individuals under its Amended and Restated Inducement Equity Incentive Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
A portion of RSUs vest over 48 months with standard one-year cliff and quarterly vesting; PSUs vest based on performance metrics by the end of fiscal 2027 and may pay out at 50%–150% of target, subject to continued service.
Twist Bioscience (NASDAQ: TWST) announced financial results and business highlights for the fiscal first quarter 2026 ended December 31, 2025. The company will host a conference call and live audio webcast at 8:00 a.m. ET on February 2, 2026 to discuss results.
Investors can access the webcast and register for telephone participation via the Investor Relations Events and Presentations page; the webcast replay will be available for two weeks.